Sermorelin for women: What the research actually says

Most information about sermorelin is written as if it applies to everyone the same way. But women's growth hormone patterns differ from men's, and most sermorelin research did not look at women separately. This article covers what is actually known about sermorelin for women, and where the evidence runs out.

It is educational and not medical advice. Sermorelin is a compounded prescription medication, and whether it fits you is a decision for a licensed provider.

What sermorelin is

Sermorelin is a growth hormone-releasing hormone (GHRH) analog. It is a shortened form of the GHRH your hypothalamus already makes, made up of its first 29 amino acids [1]. Rather than supplying growth hormone directly, it signals your pituitary gland to release its own.

Sermorelin was once FDA-approved under the brand name Geref, for diagnosing and treating growth hormone deficiency in children [1]. That product was later discontinued by its manufacturer. Sermorelin today is a compounded medication. Compounded medications are not FDA-approved, and the FDA does not evaluate them for safety, effectiveness, or quality. The former FDA approval of Geref does not extend to compounded sermorelin products. Historical Geref studies may still inform what is known about sermorelin pharmacology and safety, but they do not establish the safety, effectiveness, quality, or equivalence of a currently compounded product. For more on how it is prescribed, see the sermorelin medication page.

How the GHRH axis works in women

Growth hormone is released in pulses, mostly during sleep. GHRH from the hypothalamus prompts each pulse, and another hormone, somatostatin, acts as a brake. Growth hormone then signals the liver to make IGF-1, which carries out many of its effects.

This system is not identical in women and men. In a classic study of 24-hour growth hormone patterns, women had higher average growth hormone levels than men [2]. Those levels tracked with estradiol, the main form of estrogen [2]. The same study found growth hormone secretion declined with age in both sexes [2].

Estrogen's route of delivery also matters. In postmenopausal women, oral estrogen lowered IGF-1 levels, while estrogen delivered through the skin did not have the same effect [3]. This difference is thought to reflect the hepatic first-pass effects of oral estrogen. It is one reason a woman's hormone history matters when anyone considers a treatment that acts on this axis.

What research with women shows

Here is the honest summary: very little sermorelin research has looked at women specifically.

The most relevant study included 10 women and nine men aged 55 to 71 [4]. After four weeks of placebo injections, participants injected a closely related GHRH(1-29) analog nightly for 16 weeks [4]. Key findings [4]:

• Nightly growth hormone output rose significantly in women and in men.
• IGF-1 rose within two weeks, then drifted back toward baseline by 16 weeks in both sexes.
• Several of the measured responses were larger in men than in women.

That study is small, short, and used an analog closely related to sermorelin rather than the identical compound. The original Geref trials were in children, not adult women [1]. Larger, longer studies in adult women are missing. So any claim about what sermorelin will do for a woman specifically goes beyond what the research shows.

For a broader look at outcomes over time, see sermorelin before and after. Results vary from person to person.

Setting realistic expectations

Because sermorelin works through your own pituitary, the response depends partly on how your pituitary is functioning. That is one reason results differ from person to person.

It also helps to know what the research actually measured. In the study that included women. There is insufficient evidence to conclude that sermorelin improves body composition, energy, sleep, sexual function, appearance, cognition, or longevity in otherwise healthy adult women [4]. Even those changes were not steady: IGF-1 increased early during treatment, but the increase was not sustained to the same degree throughout the full treatment period [4]. Researchers have not established what, if any, visible or lasting changes women can expect.

That does not mean sermorelin has no effect. It means expectations should match a small, early evidence base rather than marketing claims.

Do women need different doses?

Published research does not establish a separate sermorelin dose for women.

• The original pediatric label used a weight-based dose given once daily at bedtime [1].
• The most relevant adult study used a closely related GHRH(1-29) analog rather than sermorelin itself [4].

Neither set a female-specific protocol. Because women's baseline growth hormone patterns and estrogen exposure differ, a provider may take those factors into account. Your provider determines whether sermorelin is appropriate, and at what dose. For what labels and studies use, see our guide to sermorelin dosage.

Side effects: is the profile different for women?

There is no good evidence that sermorelin's side effects differ by sex, mainly because no study has compared them directly.

The most detailed side-effect data come from the original Geref trials. In those trials, about one in six patients had an injection-site reaction, such as pain, swelling, or redness [1]. Headache, flushing, dizziness, drowsiness, and hives were each reported in less than 1% of patients [1]. Those trials were in children, so they may not fully reflect adult women's experience.

Like any prescription medication, sermorelin carries risks and possible side effects your provider will review with you. Because sermorelin stimulates the GH/IGF-1 axis, clinicians generally avoid GH-promoting therapy in patients with active malignancy. However, contemporary safety evidence specific to compounded sermorelin is limited. For the full picture, see our article on sermorelin side effects.

Pregnancy and breastfeeding

Because there are inadequate safety data in pregnancy and lactation, Luvo does not prescribe sermorelin during pregnancy or breastfeeding. If you are pregnant, trying to conceive, or breastfeeding, tell your provider before starting. If you become pregnant while using sermorelin, stop and contact your provider right away.

Menopause, birth control, and other hormones

Women's hormone patterns change across life stages, and that makes context important. What the published research supports is limited:

• Estrogen affects the growth hormone axis. Oral estrogen lowered IGF-1 in postmenopausal women, while estrogen through the skin did not [3]. If you use oral estrogen, a patch, or a gel, your provider should know.
• Growth hormone patterns track with estradiol in women [2].

Beyond that, we found no published studies of sermorelin specifically in women using hormonal birth control or menopausal hormone therapy. Rather than guess, the safest approach is to share your full hormone history, including birth control and any hormone therapy, with your provider. Questions about your hormone therapy itself belong with the clinician who manages it.

Common questions

Is sermorelin safe for women?
Historical pediatric trials were dominated by relatively mild adverse events such as injection-site reactions, but adult and long-term safety data are limited [1,4]. Whether it is appropriate for you is a decision for a provider who knows your history.

Do women need different doses?
No female-specific dose has been established. The one study that included women used the same weight-based dose for both sexes [4]. Your provider sets and adjusts your dose.

Can I use it during menopause?
That depends on your health history and any hormone therapy you use. It is a decision to make with your provider. Because oral estrogen can lower IGF-1, your provider needs to know exactly what you take [3]. Questions about the hormone therapy itself belong with the clinician who manages it.

Does it affect fertility or menstrual cycles?
There are no published studies of sermorelin's effects on fertility or menstrual cycles in women. The women in the most relevant study were 55 to 71, so cycles were not part of the research [4]. If you are trying to conceive or have irregular cycles, raise it with your provider before starting.

Questions to bring to your provider

If you are considering sermorelin, these questions can help the conversation:

• Is there anything in my hormone history, including birth control or hormone therapy, that affects whether this fits me?
• How does my age or menopausal status change the picture?
• What side effects should I watch for, and when should I call?
• How will we decide whether to continue, adjust, or stop?
• What would make sermorelin a poor fit for me?

How a provider approaches it

A provider considering sermorelin for a woman typically reviews:

• Age and menopausal status
• Current or past use of birth control or hormone therapy
• Pregnancy plans and breastfeeding
• Any history of cancer
• Other medications and health conditions

Luvo does not run lab tests. If your provider decides any bloodwork is relevant, it is arranged through your own provider or physician.

Next steps

If any of this sounds like what you are dealing with, the next step is a conversation with a licensed provider who can review your history and decide whether treatment makes sense for you. Nothing is prescribed or shipped without that review.

Explore Luvo's Longevity Program.